India Approves QDENGA, Its First Dengue Vaccine

Kolkata, July 20, 2026: Takeda Biopharmaceuticals India Pvt. Ltd. today announced that the Drug Controller General of India (DCGI) has granted market authorization for QDENGA (TAK-003), making it the first dengue vaccine approved in India for the prevention of dengue disease in individuals aged 4–60 years.

Designed to protect against all four dengue virus serotypes, QDENGA can be administered regardless of prior dengue exposure and does not require pre-vaccination testing. The approval comes at a crucial time as India continues to face a significant dengue burden, accounting for nearly one-third of global cases.

Peter Streibl, General Manager, Southeast Asia and India Cluster, Takeda, said dengue requires coordinated action across governments, healthcare professionals and communities to deliver sustainable, evidence-based prevention solutions.

Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster, said India has a substantial dengue burden, with all four virus serotypes circulating in several regions. He noted that QDENGA is designed to protect against all four serotypes regardless of prior exposure, strengthening India’s comprehensive dengue prevention efforts.

“Dengue is a growing public health challenge, and India needs sustained, evidence-based prevention,” said Dr. Mahender Nayak, Head of Intercontinental Markets, Takeda. “The approval of QDENGA marks an important step forward in strengthening dengue prevention in India, and we remain committed to working with public health authorities, healthcare professionals and partners to support equitable and sustainable access.”

QDENGA has been approved in 43 countries, has received WHO prequalification, and more than 32 million doses have been distributed globally through public and private immunization programmes.

Post Views: 15